Hormone therapy, explained for supporters
Original guidance written for MenoHealth by its editorial team. · 10 min read · Oct 2026
Medically reviewed by Karla F. Loken, DO, FACOOG on October 13, 2026
Hormone therapy is the most effective treatment for hot flashes and night sweats, and the most misunderstood. What it is, what it does, and how its benefits and risks are weighed today.
In brief
- What this helps with. What hormone therapy is, what it does, and how its benefits and risks are weighed today.
- One thing to do. Do not forward headlines about hormone risks. Ask what she wants to know instead.
- One thing to ask. "How are you finding it, and is there anything you'd want me to know?"
She came home from the appointment with a prescription for estrogen and a look that said she was not sure about it. Somewhere in the back of your mind is a headline about hormones and breast cancer. Before you say a word about it, read this.
What it is
Menopausal hormone therapy replaces some of the estrogen her ovaries have stopped making. If she still has a uterus and takes systemic estrogen, the kind that reaches the whole body, she also needs to take a progestogen, either progesterone itself or a similar hormone, because estrogen on its own thickens the uterine lining and the progestogen protects it. A woman who has had a hysterectomy usually only takes estrogen alone or adds progesterone for other reasons like sleep.
Systemic estrogen comes as pills, skin patches, gels and sprays. There is also local vaginal estrogen, as a cream, tablet, insert or ring, which treats vaginal and urinary symptoms directly and puts very little hormone into the rest of the body. Low-dose vaginal estrogen generally does not need an added progestogen.
What it does
For hot flashes and night sweats, hormone therapy is the most effective treatment there is. When night sweats are what wake her, sleep improves along with them. It prevents the bone loss that follows menopause and reduces fractures. Low-dose vaginal estrogen relieves dryness, pain with sex and urinary symptoms, and those tend to get worse rather than better without treatment. In perimenopause, estrogen may also help low mood for some women, although it is not a treatment for depression on its own.
How benefits and risks are weighed today
The Menopause Society's 2022 position statement puts it this way. For women with bothersome symptoms who are under 60 or within ten years of menopause and have no contraindications, the benefits of hormone therapy generally outweigh the risks. Age, years since menopause, her history and the type and route of hormone all move the calculation, so the decision is individual, revisited over time, and has no fixed stopping age. Hormone therapy is prescribed for symptoms and bone protection. It is not recommended to prevent heart disease.
In 2025 and 2026 the Food and Drug Administration began removing the broad boxed warnings about heart disease, breast cancer and dementia from hormone therapy products.
A short history
The Women's Health Initiative was a large randomized trial of hormone therapy in older women. In 2002 the investigators stopped the combined estrogen and progestin arm early, because the women taking it had more breast cancers, heart attacks, strokes and blood clots than the women taking placebo. The absolute differences were small, a handful of extra cases per ten thousand women per year, but prescriptions collapsed. The average participant was in her early 60s and the trial tested one oral formulation, so its results describe that group best.
The same women were followed for eighteen years. In 2017 the investigators reported that neither regimen increased the risk of dying from any cause over that period. That is a finding about deaths, not about illness. The higher rate of breast cancer diagnoses with combined therapy still stands, which is why the risk section below matters.
A separate trial, ELITE, measured a surrogate marker, the thickness of the carotid artery wall, rather than heart attacks or strokes. Women who started estradiol within six years of menopause showed slower thickening than women who started ten or more years after. That result informed the timing hypothesis, the idea that when treatment starts matters, which is now widely accepted although its finer points are still debated. It does not show that hormone therapy prevents heart disease or dementia. We also have other trials that show starting HRT more than ten years from menopause can increase risk of cardiac events and strokes. This is why we hesitate to put women on estrogen or HRT if it's been a very long time. We do have alternatives for their symptoms.
The risks, stated plainly
Hormone therapy is not risk-free, and she deserves to hear that from you as calmly as the benefits.
- Breast cancer. Combined estrogen and progestogen therapy carries a small increase in breast cancer risk that grows with years of use and varies with the type of progestogen. Estrogen alone, in women who have had a hysterectomy, did not raise breast cancer risk in the same trial.
- Blood clots and stroke. Oral estrogen raises the risk of clots. Estrogen through the skin appears to raise it much less, which is one reason patches and gels are often preferred.
- Contraindications. A history of breast cancer, certain blood clots, unexplained vaginal bleeding and some other conditions rule hormone therapy out or change the calculation. The list is longer than this, which is why the decision needs a clinician who knows her history.
What the first months look like
The first prescription is a starting point, not the final answer. It is common to adjust the dose or switch from a pill to a patch after a few weeks. Early side effects such as breast tenderness, bloating, headaches and light spotting are common and often settle in the first months. Bleeding that is persistent or heavy is different. It needs prompt reporting to her clinician rather than waiting for the next scheduled visit. Hot flashes usually improve within weeks. A follow-up visit a few months in is normal, and so is a second adjustment after it.
The word "bioidentical"
She may hear that "bioidentical" hormones are safer or more natural. The word describes hormones with the same molecular structure as the ones her body makes. Estradiol and micronized progesterone approved by the Food and Drug Administration are bioidentical in exactly that sense. Custom-compounded products, mixed to order by a pharmacy, use the same word but do not go through the same testing, quality control or safety monitoring, and the 2022 position statement advises against them except in narrow circumstances. If she is offered something compounded, that is worth a question, not an alarm. Bioidentical is a marketing term, so don't be fooled by it. Several FDA-approved hormone therapies are bioidentical too.
Your role
Do not relay headlines. If she asks what you have heard, tell her what is in this article and that her clinician has the current evidence. Ask what she wants to know, and let that set how much you say. Some women want a partner who has read the position statement. Others want nothing more than "that sounds like a reasonable plan."
Support the follow-up. Side effects get noted for the next visit, and the second appointment is as important as the first. Be the person who makes it easy to keep.
Never pressure her in either direction. Talking her onto hormone therapy because you want the night sweats to stop is as wrong as talking her off it because of a story you read. Both decisions belong to her and her clinician.
Where to start this week
- If she has started hormone therapy, ask "how are you finding it?" and leave the medical questions to her clinician.
- If she is weighing it, ask what would help her decide, and offer to read this article alongside her.
- Do not forward articles, screenshots or headlines about hormone risks.
- Keep her follow-up appointment on the shared calendar if she wants it there, or send a reminder the day before if you live apart.
Related reading
- Nonhormonal options for hot flashes and sleep
- Encouraging her to get care without pushing
- Making the most of her doctor's appointment
Frequently asked questions
Is HRT safe?
Hormone therapy is not risk-free, but for healthy women with bothersome symptoms who are under 60 or within ten years of menopause, The Menopause Society finds the benefits generally outweigh the risks. In 2025 and 2026 the FDA began removing the broad boxed warnings about heart disease, breast cancer and dementia from these products. Age, time since menopause, health history and the type and route of hormone all shift the balance, so the decision belongs to her and her clinician.
Does HRT cause breast cancer?
Combined estrogen and progestogen therapy carries a small increase in breast cancer risk, under one extra case per 1,000 women per year of use, which grows with longer use and may vary by progestogen type. In the Women's Health Initiative, estrogen alone, in women without a uterus, did not raise breast cancer risk. A history of breast cancer generally rules out systemic hormone therapy, so the decision needs her clinician.
How long can a woman stay on HRT?
There is no fixed stopping age for hormone therapy. The Menopause Society's 2022 position statement describes the decision as individual and revisited over time, based on a woman's age, years since menopause, her history and the type and route of hormone. For women whose ovaries were removed, or stopped working before 40, guidance supports hormone therapy at least until the average age of natural menopause when there is no contraindication. Follow-up visits are where the plan gets adjusted.
Is an estrogen patch safer than pills?
For blood clots, estrogen through the skin appears to be safer than estrogen taken as a pill. Oral estrogen raises the risk of clots, and estrogen delivered by patch or gel appears to raise it much less, and possibly the risk of stroke too, which is one reason patches and gels are often preferred. Hormone therapy is still not risk-free. The route is one of several things a clinician weighs alongside her age, years since menopause and history.
Sources
- The Menopause Society. The 2022 Hormone Therapy Position Statement of The North American Menopause Society. Menopause. 2022;29(7):767-794.
- Rossouw JE, Anderson GL, Prentice RL, et al. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the Women's Health Initiative randomized controlled trial. JAMA. 2002;288(3):321-333. Randomized trial, n=16,608, combined-therapy arm stopped early.
- Manson JE, Aragaki AK, Rossouw JE, et al. Menopausal hormone therapy and long-term all-cause and cause-specific mortality: the Women's Health Initiative randomized trials. JAMA. 2017;318(10):927-938. Cumulative 18-year follow-up.
- Hodis HN, Mack WJ, Henderson VW, et al. Vascular effects of early versus late postmenopausal treatment with estradiol. New England Journal of Medicine. 2016;374(13):1221-1231. ELITE randomized trial.
- The Menopause Society. The 2020 Genitourinary Syndrome of Menopause Position Statement of The North American Menopause Society. Menopause. 2020;27(9):976-992.
- Maki PM, Kornstein SG, Joffe H, et al. Guidelines for the evaluation and treatment of perimenopausal depression: summary and recommendations. Menopause. 2018;25(10):1069-1085.
- U.S. Food and Drug Administration. Menopausal hormone therapy labeling action (announced 10 November 2025, first approvals 12 February 2026).
Disclaimer
This article is for education and support. It is not medical advice, and it is not a substitute for care from a qualified healthcare provider. Decisions about treatment, including hormone therapy and other prescription medicines, belong to the person experiencing menopause and her clinician.
